SEC Form 4 · accession 0001562180-19-000252
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Jonas
Officer — President & CEO · Director
Period of report
Jan 9, 2019
Accepted (ET)
Jan 10, 2019 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 9, 2019 | M | 10,000 | $0.45 | A | 62,115 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.45 | Jan 9, 2019 | M | 10,000 | D | — | Aug 12, 2023 | Common Stock | 10,000 | 221,987 | D |
Explanation of responses
- F1Reflects beneficial ownership balance which includes ESPP shares owned as of December 31, 2018.
- F2The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017.